CDK4 and neoplasm: Rb, a tumor suppressor, represents the primary target of CDK4/6i, and loss of Rb function, due to mutations or deletions, emerged in preclinical and clinical studies as a driver of both intrinsic and acquired resistance to CDK4/6i.